Revenue (Tables)

12 Months Ended

Dec. 31, 2024

Disaggregation of Revenue [Abstract]

Schedule of Revenue Disaggregated by Customer Type

The following table presents the Company's revenue disaggregated by customer type (in thousands):


		Year Ended December 31,
		2024				2023
Pharma tests and services (1)		$	50,939			$	31,904
Enterprise sales			25,364				31,729
Population sequencing			7,430				9,412
Clinical diagnostic			759				38
Other			122				398
Total revenue		$	84,614			$	73,481

(1) Includes related party revenue of $2.0 million for the year ended December 31, 2024.

Schedule of Contract Assets and Liabilities

The opening and closing balances of receivables and contract liabilities from contracts with customers are shown below (in thousands). Contract assets were immaterial for all periods presented.


		December 31,
		2024				2023
Opening balances:
Accounts receivable, net		$	17,730			$	16,642

Short-term contract liabilities		$	3,288			$	1,264
Long-term contract liabilities (included in other long-term liabilities)			3,928				—
Total contract liabilities			7,216				1,264

Closing balances:
Accounts receivable, net		$	8,140			$	17,730

Short-term contract liabilities		$	3,100			$	3,288
Long-term contract liabilities (included in other long-term liabilities)			—				3,928
Total contract liabilities			3,100				7,216